BioSolar (OTCMKTS:BSRC) recently made an announcement through a Form 8-K filing on October 22, 2024. The company, operating under the name NewHydrogen, Inc., shared details about a notable event involving its Chief Executive Officer, Steve Hill.
In a press release issued on the same day, NewHydrogen, Inc. revealed that CEO Steve Hill engaged in a discussion during a podcast with Dr. Christopher Cadou. The podcast showcased a dialogue between Steve Hill and Dr. Christopher Cadou, who holds the position of Keystone Professor in the University of Maryland’s A. James Clark School of Engineering. The specifics of this enlightening conversation were not disclosed in the Form 8-K filing.
Additionally, the filing under Item 9.01 highlighted the submission of Financial Statements and Exhibits. Among these was a Press Release dated October 22, 2024 (Exhibit 99.1).
Moreover, following the necessary reporting requirements, NewHydrogen, Inc. ensured compliance by furnishing pertinent details related to the event, thereby providing transparency to stakeholders and interested parties.
This press release serves as an affirmation of the active engagement of BioSolar, working under the name NewHydrogen, Inc., in collaborative discussions and partnerships with experts in the field. Such interactions contribute to the ongoing growth and development of the company’s strategic initiatives.
END
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BioSolar’s 8K filing here.
BioSolar Company Profile
BioSolar, Inc engages in developing clean energy technologies and materials for storing electrical energy produced by photovoltaic solar modules. It offers BioBacksheet, a green back sheet for photovoltaic solar modules. The company focuses on developing silicon alloy-based anode materials for lithium-ion batteries.
See Also
- Five stocks we like better than BioSolar
- The Risks of Owning Bonds
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Trading Halts Explained
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?